Hemogenyx Pharmaceuticals PLC Investor presentation
08 Giugno 2018 - 8:00AM
RNS Non-Regulatory
TIDMHEMO
Hemogenyx Pharmaceuticals PLC
08 June 2018
Hemogenyx Pharmaceuticals Plc
("Hemogenyx" or the "Company")
Investor presentation
Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology
company developing novel therapies to transform bone marrow, or
blood stem cell, transplantation for the treatment of blood
diseases, announces that it will hold a presentation for investors
on Tuesday 26(th) June 2018.
The briefing by Dr. Vladislav Sandler, CEO of Hemogenyx, will
take place at Copper Bar, Balls Brothers, 6 Adams Court, Old Broad
Street, EC2N 1DX from 4.30pm for a 4.45pm start and will be
followed by drinks and networking. If you would like to register to
attend, please contact Walbrook PR on 020 7933 8780 or email
hemogenyx@walbrookpr.com
Enquiries:
Hemogenyx Pharmaceuticals Limited www.hemogenyx.com
Dr Vladislav Sandler, Chief Executive Via Walbrook PR
Officer & Co-Founder
Sir Marc Feldmann, Chairman
Optiva Securities Ltd Tel: +44 (0)20 3137 1902
Christian Dennis
Shard Capital Partners LLP Tel: +44 (0)20 7186 9950
Damon Heath, Erik Woolgar
Peterhouse Corporate Finance Limited Tel: +44 (0)20 7469 0930
Lucy Williams/Duncan Vasey
Walbrook PR Tel: +44 (0)20 7933 8780 or hemogenyx@walbrookpr.com
Paul McManus
Mob: +44 (0)7980 541 893
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE:
HEMO) headquartered in London, with its wholly owned U.S. operating
subsidiary, Hemogenyx LLC, located in its state-of-the-art research
facility in Brooklyn, New York. Hemogenyx is a preclinical-stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel therapies and treatments for blood
diseases such as leukemia and lymphoma. The company's leading
technologies aim to change the way in which bone
marrow/hematopoietic stem cell (BM/HSC) transplants are performed
and improve their efficacy. Hemogenyx's two distinct and
complementary products include an immunotherapy product for patient
conditioning-the CDX bi-specific antibody-and a cell therapy
product for BM/HSC transplantation-the HuPHEC. Each of these
products holds the potential to revolutionize the way BM/HSC
transplants are being performed, offering solutions that mitigate
the dangers and limitations associated with the current standard of
care. For more information, visit www.hemogenyx.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAUBVURWWANRAR
(END) Dow Jones Newswires
June 08, 2018 02:00 ET (06:00 GMT)
Grafico Azioni Silver Falcon (LSE:SILF)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Silver Falcon (LSE:SILF)
Storico
Da Lug 2023 a Lug 2024